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Over 40% of patients with cirrhosis will develop hepatic encephalopathy (HE). HE is associated 
with decreased survival, falls, motor vehicle accidents, and frequent hospitalization. 
Accordingly, we aimed to develop a tool to risk-stratify patients for HE development. We 
studied a population-based cohort of all patients with cirrhosis without baseline HE (N=1,979) 
from the Veterans Administration from Michigan, Indiana, and Ohio (1/1/2005-12/31/10) using 
demographic, clinical, laboratory, and pharmacy data. The primary outcome was the 
development of HE. Risk-scores were constructed with both baseline and longitudinal data 
(annually updated parameters) and validated using bootstrapping. The cohort had mean age of 
58.0±8.3 years, 36% had hepatitis C, 17% had ascites. Opiates, benzodiazepines, statins, and 
nonselective beta-blockers were taken at baseline by 24%, 13%, 17%, and 12%. Overall, 
863(43.7%) developed HE within 5 years. In multivariable models, risk factors (HR, 95%CI) for 
HE included higher bilirubin (1.07, 1.05-1.09) and nonselective beta-blocker use (1.34, 1.09-
1.64), while higher albumin (0.54, 0.48-0.59) and statin use (0.80, 0.65-0.98) were protective. 
Other clinical factors, including opiate and benzodiazepine use were not predictive. The AUROC 
for HE using the 4 significant variables in baseline and longitudinal models were 0.68 (0.66-
0.70) and 0.73 (0.71-0.75), respectively. Model effects were validated and converted into a risk 
score. A score <0 in our longitudinal model assigns a 6% 1-year probability of HE while a score 
>20 assigns a 38% 1-year risk. 
Conclusion: Patients with cirrhosis can be stratified by a simple risk-score for HE that accounts 
for changing clinical data. Our data also highlight a role for statins in reducing cirrhosis 
complications including HE. 
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Cirrhosis is the final common pathway for most chronic liver diseases.(1) The majority of 
patients with compensated cirrhosis in the United States (US) live more than a decade after 
diagnosis.(2) A diagnosis of cirrhosis should prompt changes in management that include 
intensified treatment of the underlying disease, lifestyle changes, and counselling regarding 
prognosis and the risk of decompensation. Of the clinical complications of cirrhosis (variceal 
hemorrhage, ascites, and hepatic encephalopathy (HE)), HE is the most devastating. HE is a 
spectrum of reversible cognitive changes that range from mild inattention and deficits of 
executive function to lethargy, disorientation, and even coma.
3-6 
Over 40% of patients with 
cirrhosis will ultimately develop HE,(3) an event that is associated with decreased survival,(4) 
falls,(5) and motor vehicle accidents.(6, 7)  HE is also the most important factor predicting 
hospitalization and readmission.(8, 9) Following the development of HE, a patient’s one-year 
overall mortality may rise to >60%.(10) Unfortunately, data guiding the stratification of patients 
with cirrhosis according to their risk of HE are limited and risk scores to predict HE development 
are not available. There are also no data to inform patients on how their risk changes after 
experiencing an improvement in liver function, for example, after cure of hepatitis C or alcohol 
abstinence. Similarly, for clinicians, there is no guidance regarding the impact on the risk of HE 
from common medications used in patients with cirrhosis. Herein, we analyze a large cohort of 
Veterans with cirrhosis followed for up to 5 years in order to determine a risk score for the 
development of HE and to quantify the effect of medications on the risk of HE. 
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 Consistent with the Food and Drug Administration’s BEST (Biomarkers, EndpointS, and 
other Tools) terminology, we aimed to develop a risk biomarker or risk score.(11) We therefore 
report results of our study in accordance with the recommended framework by the Transparent 
reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) 
statement (online supplement)(12) We performed a retrospective cohort study of all adult 
Veterans from the Veterans Affairs Integrated Service Network (VISN) 11 with cirrhosis seen in 
any VA facility for any outpatient or inpatient visit between 1/1/2005-12/31/2010. VISN 11 was 
one of the 20 integrated service networks within the VA healthcare system and provides inpatient 
and outpatient care for more than 685,000 Veterans within an area including Michigan, central 
Indiana, and northwest Ohio. In 2016, VISN 11 was absorbed into VISN 10. We used a validated 
definition of cirrhosis that is associated with a positive predictive value >91% in this setting.(13) 
Specifically, we enrolled patients with billing codes for cirrhosis (ICD-9: 571.2, 571.5, 571.6) 
and an Aspartate Aminotransferase to Platelet Ratio Index (APRI) > 2.0 or a code for one of the 
cirrhosis complications, including varices, ascites, or spontaneous bacterial peritonitis (456.0-
456.2, 572.3, 572.4, 572.8, 789.5). We excluded all patients with HE (as defined by a 572.2 code 
or lactulose/rifaximin prescriptions) at the time of enrollment. We included the use of lactulose 
or rifaximin to increase sensitivity for HE because while the 572.2 code has excellent positive 
predictive value (91.5%-94.3%) for HE, its negative predictive value is low (36.1%).(14, 15) 
Further, we limited our dataset to patients with at least 90 days of clinical follow-up. Overall, 
2,747 patients had a cirrhosis diagnosis, 2,170 of whom had either a complication or an APRI > 
2.0. After excluding 191 patients with an HE diagnosis at baseline, our final cohort included 
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1,979 patients. The institutional review board of the Ann Arbor Veterans Administration 
approved the study prior to data collection. 
 
Outcome and predictors 
 
Our primary outcome was the development of HE. Patients were censored at the time of 
death, liver transplant, or loss-to-follow-up at time of the last clinical observation (in patients 
who did not die). Five-year survival was determined based on the VA’s Beneficiary 
Identification Records Locator Subsystem death file. For each patient, deaths were recorded from 
the beginning of the study through 5 years from their index enrollment date.  
 
Baseline predictors of HE were defined as follows: Demographic predictors were age at 
diagnosis, sex, race/ethnicity, and urban vs. rural residence(16) determined based on VA 
Planning Systems Support Group geocoding (19). Clinical predictors included the etiology of 
liver disease (viral hepatitis, alcoholic, or other cirrhosis), alcohol intake at baseline (based on 
the AUDIT-C)(17), comorbidities (based on the Elixhauser index),(18) as well as cirrhotic 
complications, each defined by their corresponding ICD-9 code or procedure code (in the case of 
paracentesis).(Table 1) Laboratory predictors included standard parameters (albumin, total 
bilirubin, international normalized ratio (INR), creatinine, sodium, platelet count) as well as 
transformed variables such as the Model for Endstage Liver Disease (MELD).(19) 
Pharmacological predictors included any filled prescription (>30 day supply) for several classes 
of medication. The medication classes were selected on the basis of their association with 
cirrhotic conditions (diuretics/ascites, beta-blockade/varices), reported negative or positive 
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associations with cirrhotic complications (statins,(20) metformin,(21) and proton pump 
inhibitors(22)), and psychoactive medications that may have increased risk of  adverse events in 
patients with cirrhosis (opiates, benzodiazepines, antidepressants, and antipsychotics).(5) 
Medications were searched using generic and brand names, and both short and long acting 
formulations.(Supplemental Table 1) For the purpose of longitudinal modeling, we included 
updated laboratory data and interval filled prescriptions of each medication class. Statistical 
analyses were performed using STATA version 14 (College Station, TX) and R version v.vv 
(CRAN). 
 
Analysis: Baseline data 
 
Pearson’s χ2-tests and Student’s t-tests were used as appropriate for bivariate analyses of 
categorical and continuous predictors of HE, respectively. Multivariable Cox proportional hazard 
analysis was performed to determine independent predictors with candidate variables identified 
from univariate analyses with significant associations (p< 0.1). Variables with missing data were 
not entered into final models. Age, sex and comorbidity were included in a preliminary model 
given biological plausibility despite a lack of statistical association. However, because these 
factors did not alter model performance of selected factors, they were excluded for parsimony. 
Based on the regression coefficients of significantly associated variables in the Cox model, a risk 
score was constructed using the simplest model. First, prediction accuracy was estimated using 
the area under the receiver operating characteristics curve (AUROC). We performed validity 
assessment of the model using internal validation using bootstrap.(23) Bootstrap samples are 
random samples drawn with replacement from the original sample. We repeatedly fitted the 
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model in 10,000 bootstrap samples and evaluated its performance on the original sample in order 
to obtain a measure of model optimism and bias. Higher measures of optimism would suggest a 
risk for poorer performance in external datasets. Second, the regression coefficients of the 
multiple logistic regression model were used to derive a corresponding integer scoring 
system.(24, 25) Clinical variables in the final multivariable model were organized into clinically 
meaningful ategories, each with a specific reference value. We then assigned a referent risk for 
each factor with the base risk assigned 0 points in the scoring system, with higher points 
corresponding to greater risk. Next, we calculated the difference in regression units between each 
category and the base category, and set the constant, B, as the number of regression units 
corresponding to 1 point. The points for each risk factor were calculated as the difference in 
regression units between each category and its base category divided by the constant. We then 
used the point system to divide the cohort into tertiles of risk to describe the corresponding risk 
of HE over a narrow range of scores.  
 
Analysis: Longitudinal data 
  
The analytic procedures for the 5-year risk of HE using baseline data described above 
were repeated to construct risk models using longitudinal data. In this case, clinical variables and 
medication utilization were updated to reflect the patient’s status each year using the values 
(including medication fills) obtained closest to years 1, 2, 3, 4 and 5. Each year the clinical 
variable would be updated to reflect any changes that occurred during the prior year to predict 
outcomes in the following year (until an outcome occurs or the patient is censored). Accordingly, 
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the longitudinal model provides a 1-year risk of HE for any given patient based on their most 
recent clinical parameters. 
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Clinical Characteristics of the Overall Cohort and Risk of HE 
 
Of the 1,979 patients included, the cohort had mean age of 58.0+8.3 years, and was 
predominantly male (98%) and white (74%). Overall, 36% had hepatitis C and 13% were coded 
as having alcoholic cirrhosis. Of the 371 patients with AUDIT-C scores, 150 (40%, all with 
alcoholic liver disease) scored > 4, consistent with alcohol abuse. At baseline, very few patients 
had received a paracentesis (79, 4%), however 350 (17%) had the ascites diagnosis code; 69 
(3.5%) patients had experienced variceal hemorrhage while 228 (11.5%) were taking non-
selective beta-blockers at enrollment. Opiates, benzodiazepines, proton pump inhibitors (PPI), 
and statins were taken at baseline by 24%, 13%, 35%, and 17%. The average albumin, bilirubin, 
and INR were 3.40 g/dL, 1.97 mg/L, and 1.31, respectively. One hundred and sixty-one (8%) had 
platelet counts less than 100*10
9
/L. During follow up, 863 (43.6%) patients developed overt HE. 
The cumulative probabilities of overt HE at 1, 3, and 5 years was 22.6%, 36.9%, and 43.6%, 
respectively. The median time to the development of HE from study enrollment was 340 days 
(IQR 71-842). Median survival time was 747 days for those who developed HE and 1490 days 
(IQR 448-1812) for those who did not develop HE. Only 16 (0.8%) underwent liver 
transplantation during the study period. 
 
Baseline characteristics of the patients who did and those who did not develop overt HE 
are delineated in Table 1. Demographics, etiology of liver disease, and presence of cirrhosis 
complications were comparable in the two groups. Patients who developed HE had lab values 
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suggesting more advanced liver disease: higher bilirubin and lower albumin values but creatinine 
values were lower. Baseline use of sedating, pain and anti-psychotic medications was similar, 
except for o iate use which was paradoxically more common in patients who did not develop HE 
(26.3% vs 21.2%, P<0.009). Of the medications examined, the biggest difference between the 
two groups was a significantly lower use of statins in patients who developed HE (13.3% vs 
19.2%, p=0.0005). Non-selective beta-blocker use was associated with increased risk of HE, 
(13% of those who developed HE versus 10.4% of those who did not develop HE; HR1.27, 95% 
CI 1.04-1.55). Of the 230 patients taking beta-blockers, the vast majority (79.6%) were receiving 
propranolol.   
 
Adjusted Associations with HE Risk Over Time 
 
Table 2 details the associations of baseline variables with the development of HE over 
time in Cox proportional hazards models. Variables with significant associations on univariate 
analysis included the presence of ascites (by ICD code), receipt of paracentesis, total bilirubin, 
INR, albumin, serum sodium, and use of opiates, non-selective beta-blockers and statins. In 
multivariable adjustments, only baseline bilirubin (hazard ratio (HR) 1.066), albumin (HR 
0.532), statin use (HR 0.795) and non-selective beta-blocker use (HR 1.338) were associated 
with the development of HE.  
 
Predicting Short- and Long-Term Risk of HE 
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Baseline models provide estimates of 5-year risk of HE, while longitudinal models 
provide an annual estimate of risk using updated parameters. The area under the receiver 
operating characteristic curves (AUROC) with 95% confidence intervals (95%CI) for the 
development of HE for predictive models using baseline values of the four predictors: total 
bilirubin, albumin, statin use, and non-selective beta-blocker use is 0.68 (0.66-0.70). The bias 
obtained from this estimate in the internal validation procedure was 0.00045 (standard error 
0.0095), suggesting limited optimism (i.e. after correcting the c-statistic, the result is still 0.68). 
When the longitudinal model for annual risk of HE was executed with the same variables, the 
resulting AUROC was 0.73 (0.71-0.75). The performance of neither baseline nor longitudinal 
models improved when bilirubin was replaced by the MELD score (c-statistic 0.68 for both 
MELD and MELD-Na) or when use of other medications: proton pump inhibitors, opiates, 
benzodiazepines, anti-depressants, gabanergic medications singly or in combination was added 
to the model. (Supplementary Table 2)  
 
Constructing a Risk Score for Short- and Long-Term Risk of HE 
Risk scores using both baseline and longitudinal data are presented in Table 3 and the 
frequency distribution of the scores is delineated in Supplementary Figure 1. The median 
(range) risk scores in baseline and longitudinal models were, respectively, 8 (-23 to 62) and 9 (-
17 to 59). The risk strata for the baseline and longitudinal models were <-10, -9 to 20, and >21; 
and <0, 1-20, and >21, respectively. The proportion of patients with low, intermediate, and high 
baseline risk score who had developed HE is depicted in Figure 1. A Kaplan-Meier curve is 
presented in Figure 2 to illustrate the clear separation of risk curves between the 3 categories of 
risk score selected in Figure 1. In the baseline model, a score of ≤-10 was associated with a 5-
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year risk of HE of 27% while a score >-10 was associated with a 5-year risk of HE  >49%. In the 
longitudinal model, which factored in changes of labs and medications, the break point for 
increased risk was a score of  >1.  A score of <0 was associated with a 6% risk of HE in the 
following year, while a score of  ≥ 1 was associated with a 25% risk of HE over the following 
year. A score <0 in the longitudinal model carried an 89% (95% CI, 88-90%) negative predictive 
value for the development of overt HE. In the baseline model, a cutoff of >-11 provides 90.7% sensitivity 
and a cutoff of >27 provides 91.2% specificity. In the longitudinal model, a cutoff of >-3 provides 90.3% 
sensitivity while a cutoff of >19 provides 90.6% specificity. 
  
Page 13 of 31
Hepatology
Hepatology














 Hepatic encephalopathy (HE) is a devastating complication of cirrhosis. Accurate 
prognostics and preventative measures are lacking. To bridge this gap, we developed a simple, 4-
component risk score for HE that can be used during the routine evaluation of outpatients with 
cirrhosis.   
 
Why the score works 
 First, two components of the risk score were low albumin and high bilirubin levels 
suggesting that the primary driver of HE risk is the severity of liver dysfunction. Albumin and 
bilirubin comprise 2 of 3 objective components of the Child-Turcotte-Pugh (CTP) score, an 
established measure of severity of liver disease. We did not analyze CTP score as ascertaining 
the severity of ascites and HE from administrative data is challenging. Furthermore, our outcome 
of interest is HE which is included in the CTP score. Second, we found that non-selective beta-
blocker use was associated with increased risk of HE. Given that nonselective beta-blockade is 
used for primary and secondary prophylaxis of variceal hemorrhage, this finding is likely a proxy 
for high-risk varices or severe portal hypertension. Third, emerging data support a beneficial role 
of statin in cirrhosis and our findings are confirmatory. The mechanism of statin’s benefit may 
relate to a salutary  effect on portal pressures (by modulating intrahepatic endothelial 
dysfunction) , as established in controlled studies(26). These findings have been extrapolated to 
explain the beneficial effects of statins on mortality and decompensation.(27, 28).(29) A meta-
analysis of four observational studies examining the effects of statins on hepatic decompensation 
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found a robust effect (relative risk 0.54, 95% CI 0.46–0.62; I
2
=0%) but no specific data on HE 
were provided.(20) Beyond portal pressure changes, statins have well known anti-inflammatory 
and immunomodulatory properties.(30) Since portal hypertension leads to shunting of ammonia 
and inflammation enhances ammonia-induced neurotoxicity,(31) the effects of statins in 
preventing HE is plausible.  
 
How to use the risk score 
 Given the harms associated with HE, it is currently recommended that patients with 
cirrhosis undergo screening. Specifically, the American Association for the Study of Liver 
Diseases recommends patients with cirrhosis be assessed for covert HE,  a precursor of overt HE 
characterized by executive function deficits and decreased reaction speeds.(32) The goal of this 
recommendation is to identify at-risk patients and provide counselling (particularly regarding 
driving and nutrition) and even consider pharmacotherapy (i.e. lactulose or rifaximin). 
Unfortunately, in order to diagnose covert HE, one must consult a neuropsychologist for 
batteries of psychological tests that are administered and scored against local reference data.(31) 
Given the complexity and cost of its assessment, most patients are not screened.(33) Though 
there are promising alternative methods (e.g. EncephalApp), none have been validated in clinical 
practice to predict clinical outcomes. In order to increase the screening of cirrhosis patients at 
risk for HE, the tests used must be simple, low cost, and can be applied during routine clinical 
follow up. Our 4-component risk score meets these criteria. To enhance clinical utility, we 
provided cutoff values to maximize sensitivity or specificity according to clinical settings. In 
general, screening tests aim to maximize sensitivity for at-risk patients; however, there may be 
circumstances when we may prefer to maximize specificity to avoid mislabeling patients as 
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having high risk for HE (e.g. compensated patients who report high quality of life(34)). As with 
the standard tests for covert HE, our score’s cutoffs also create patients with borderline or 
indeterminate results which can be difficult to interpret clinically. These results must be 
evaluated in the patient’s clinical context, prompting intermediate interventions (counselling and 
enhanced nutritional support) or viewed as a call for closer observation for decompensated 
patient. We provide estimates of 1-year risk in the longitudinal model for this reason. Given that 
neuropsychological testing is not widely available, re-defining the pre-morbid state for overt HE 
from covert HE to this risk score would substantially expand the tested population. Although the 
treatments, including improved nutrition, lactulose and rifaximin, are safe and well-tolerated, this 
strategy may lead to overtreatment. Additionally, future study is needed to confirm treatment 
response for patients with high risk scores, treating patients with covert HE often forestall the 
development of overt HE and improve quality of life.  
 
What this study adds to prior studies 
Predictors of HE have been poorly characterized and prior unadjusted estimates of HE 
risk offer little guidance. In a cohort of 293 patients, Gines et al found that the unadjusted risk of 
HE in an observational cohort of patients with cirrhosis at 3 years was roughly 20%.(2) Later,  
Jepsen using a population-based cohort of Danish patients,(10) and Sangiovanni with a 17-year 
cohort from Milan, both showed that HE developed slowly in cirrhosis patients without prior 
portal hypertensive complications.(10, 35)  Both studies neither included laboratory data in their 
risk estimates nor provided a risk assessment tool. In contrast, our study provides a tool to 
distinguish low from high risk patients using widely available markers.  Dienstag and Konerman, 
both analyzing the HALT-C cohort (a clinical trial of patients receiving long-term interferon for 
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advanced hepatitis C), and Gomez et al, analyzing an observational cohort from Cuba, both 
classified risk of decompensation as a composite outcome (including HE) with models that 
included CTP score and platelet count.(36-38) Unfortunately, the number of HE events in both 
studies (a combined 80 events out of 1400 patients),(36, 37) limited the ability to provide 
accurate prediction of HE. Moreover, prior studies did not provide tools to assess changing risk 
during follow-up. Patients at high risk for HE should be offered a suite of clinical and lifestyle 
changes to promote improved liver function. At a minimum, this includes the eradication of 
hepatitis C if present,(39) intensified treatment for alcohol abuse,(40) and specific guidance on 
nutritional intake (i.e. >1.25 g/kg protein daily),(32) each of which is associated with improved 
liver function (i.e. albumin and/or bilirubin). Additionally, there may be a chemopreventive role 
for statins. The principal advance of our simple, HE-specific risk score is that it can provide 
revised estimates as the patient’s liver function and other parameters such as use of statin 
changes. 
 
Interpreting Results in the Context of the Study Design 
The strengths of our study include a large cohort of patients with data on lab values and 
medications. We used a previously validated algorithm for identifying patients with cirrhosis 
within the VA system.(13) We analyzed not only baseline data but also longitudinal data 
simulating the effects of incident drug prescriptions and changes in lab values in prospective 
studies. However, there are several limitations that are inherent in retrospective studies. First, our 
requirement for an APRI > 2.0 or a cirrhotic complication, in addition to cirrhosis diagnosis 
codes was aimed to ensure specificity of the diagnosis of cirrhosis but it may have enriched the 
cohort with more advanced cirrhosis and higher risk of HE. compared to other studies of 
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compensated patients.(36, 37) Second, the VA patient population is predominantly male. Third, 
any retrospective data is subject to the risk of unmeasured confounders. Some factors that have 
been suggested to play a role in the development of HE such as baseline educational attainment 
(reflecting cognitive reserve)(34) and sarcopenia (muscle actively metabolizes ammonia),(31) 
could not be examined in this study. Fourth, while high bilirubin and low albumin reflecting 
severity of liver disease are likely causally related to development of HE, other predictors may 
not be causally related. Fifth, some of our data on the effects of specific drug classes conflict 
with prior reports. Our data from outpatients with cirrhosis suggests that after adjusting for 
disease severity, psychoactive medications, metformin, and PPI are not associated with the 
development of HE.(5, 21, 22) These differences can be reconciled. Many medications possess a 
narrow therapeutic index in cirrhosis. Psychoactive drugs and PPI may have incremental toxicity 
for acutely ill hospitalized patients but limited risk-adjusted adverse effects in relatively stable 
outpatients. Similarly, though not tested here, we suspect that our finding of the salutary effect of 
statins on HE risk is less likely to be observed in a cohort of infected, acutely decompensated 
hospitalized patients. The beneficial effect of metformin, a known modifier of glutaminase 
activity in vitro,(21) was established in a cohort of 80 patients with diabetes. Our sample size 
was larger, including roughly 2.5 times the number of metformin users, and by including non-
diabetic patients, our cohort is fundamentally different. Finally, propranolol made up the 
majority of betablocers used. While these were likely proxies for clinically significant portal 
hypertension, we cannot be sure these data generalize to, say, carvedilol. 
 
Conclusion 
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In summary, we found that the risk of HE in patients with cirrhosis can be stratified by 
two readily available lab tests and a brief inventory of the medication list.  Our risk score needs 
to be validated prospectively in external cohorts. Finally, the potential benefits of statins in 
preventing HE need to be studied in rigorously designed randomized controlled trials. This is 
particularly important for patients with cirrhosis for whom there is no effective treatment to 
eliminate or control the underlying cause.  
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Table 1: Cohort Characteristics 
 
 
No HE (n=1116) HE  (n=863) P Value 
Age  58.6 (9.13) 57.3 (7.83) .001
Male, n (%) 1096 (98.2) 852 (98.7) 0.36
Race/ethnicity, n (%) 
 White, not Hispanic 814 (72.9) 652 (75.6)
0.12
 White, Hispanic ethnicity 12 (1.1) 16 (1.9)
 Black 217 (19.3) 154 (17.8)
 Other 73 (6.5) 41 (4.8)
Urban/rural status: Urban, n (%) 741 (66.4) 586 (67.9) 0.48
Elixhauser comorbidity, mean (s.d.) 3.62 (2.47) 3.10 (2.30) 0.24
Hepatitis C, n (%) 395 (35.4) 312 (36.2) 0.73
Alcoholic Cirrhosis, n (%) 157 (14.1) 103 (11.9) 0.16
Variceal bleed, n (%) 33 (3.0) 36 (4.2) 0.14
Hepatocellular carcinoma, n (%) 33 (3.0) 17 (2.0) 0.17
Ascites, n (%) 194 (17.4) 146 (16.9) 0.79
Paracentesis, n (%) 44 (3.9) 35 (4.1) 0.90
Labs 
MELD score mean (s.d.) INR mean (s.d.) 1.29 (0.70) 1.34 (0.59) 0.22
Thrombocytopenia, n (%) 90 (8.1) 71 (8.2) 0.90
Creatinine, mg/dL mean (s.d.) 1.13 (0.83) 1.02 (0.68) 0.002
Bilirubin (mg/dl), mean (s.d.) 1.66 (2.42) 2.37 (3.23) < 0.0001
Albumin, g/dL mean (s.d.) 3.49 (0.73) 3.27 (0.70) <.0001
Sodium, meq/L mean (s.d.) 137.8 (4.38) 137.3 (8.28) 0.09
Medication use 
Benzodiazepine use, n (%) 145 (13.0) 107 (12.4) 0.69
Gabanergic use, n (%) 88 (7.9) 61 (7.1) 0.49
Opiate use, n (%) 293 (26.3) 183 (21.2) 0.009
Antipsychotic use, n (%) 83 (7.4) 64 (7.4) 0.99
Proton Pump Inhibitor use, n (%) 404 (36.2) 297 (34.4) 0.41
Anti-depressant use, n (%) 279 (25.0) 218 (25.3) 0.89
Tricyclic Anti-depressant use, n (%) 140 (12.5) 116 (13.4) 0.56
Diuretic use, n (%) 
 
463 (41.5) 324 (37.5) 0.08
Metformin use, n %) 95 (11.0) 129 (11.6) 0.29
Nonselective Betablocker use, n (%) 116 (10.4) 112 (13.0) 0.07
Statin use, n (%) 214 (19.2) 115 (13.3) 0.0005
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95% CI (P value) 
Hazard 
ratio 
95% CI P value 
Age 1.005 0.996-1.013 (0.27)   
Male gender 1.486 0.820-2.692 (0.19)   
Urban location 1.063 0.921-1.226 (0.40)   
Hepatitis C 0.894 0.778-1.027 (0.11)   
Alcoholic Cirrhosis 1.087 0.885-1.336 (0.43)   
Thrombocytopenia 1.084 0.850-1.382 (0.51)   
Hepatitis B 0.977 0.596-1.602 (0.93)   
Variceal bleed 1.346 0.964-1.879 (0.08)   
Hepatorenal syndrome 0.332 0.047-2.353 (0.27)   
Hepatocellular 
carcinoma 
1.069 0.661-1.728 (0.79)   
Ascites 1.480 1.238-1.769 (<.0001)   
Paracentesis 1.612 1.149-2.262 (0.006)   
Bilirubin (mg/dl) 1.103 1.086-1.121 (<.0001) 1.068 1.048-1.088 (<.0001) 
International normalized 
ratio 
1.124 1.041-1.213 (0.003)   
Creatinine 0.953 0.853-1.064 (0.39)   
Albumin 0.501 0.457-0.549 (<.0001) 0.543 0.493-0.597 (<.0001) 
Sodium 0.985 0.978-0.992 (<.0001)   
Benzodiazepine 0.877 0.717-1.074 (0.21)   
Gabanergic 0.907 0.699-1.176 (0.46)   
Opiate 0.794 0.674-0.934 (0.006)   
Antipsychotic 0.932 0.723-1.203 (0.59)   
Proton Pump Inhibitor 0.938 0.815-1.079 (0.37)   
Anti-depressant 0.908 0.778-1.058 (0.22)   
Tricyclic Anti-
depressant 
1.005 0.826-1.222 (0.96)   
Diuretic 0.943 0.821-1.082 (0.40)   
Betablocker 1.235 1.013-1.507 (0.04) 1.268 1.036-1.551 (0.02) 
Statin 0.742 0.610-0.903 (0.003) 0.740 0.608-0.901 (0.003) 
Variables that retained statistically significant associations in multivariable models are included 
in the rightmost columns and subsequently entered into the final model for risk score 
construction. 
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Table 3: Construction of a Risk Score for Hepatic Encephalopathy 
  











No 0 0 0    
Yes 1 7 8    
Statin No 0 0 0 
   
  Yes 1 -9 -4 
   
Total 
Bilirubin 
 (mg/dL)  
<0.5 0.35 -2 -2 
   
0.6-1 0.8 -1 -1 
   
1.1-1.5 1.3 0 0 
   
1.6-2 1.8 1 1 
   
2.1-2.5 2.3 2 2 
   
2.6-3 2.8 3 3 
   
3.1-4 3.55 5 5 
   
>4 10.1 18 18 
   
Albumin  
(g/dL) 
<2 1.8 37 33    
2.1-2.5 2.3 28 24    
2.6-3 2.8 19 16    
3.1-3.5 3.3 9 8    
3.6-4 3.8 0 0    
>4 4.45 -12 -11    
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Figure 1: Proportion of Patients Developing HE According to their Risk Score  
 
Left: The proportion of patients who develop HE over the course of 5 years follow-up, stratified 
by risk score category. 
Right: The proportion of patients who develop HE over the following year in a model using 
longitudinal data, stratified by risk score. 
 
Figure 2: Risk of HE from Baseline Assessment by Risk Strata 
Low risk patients have baseline risk scores of <-10, Intermediate risk patients have scores 
between -9 and 20, and high risk patients have scores >20.  
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Figure 1: Proportion of Patients Developing HE According to their Risk Score  
 
Left: The proportion of patients who develop HE over the course of 5 years follow-up, stratified by risk score 
category.  
Right: The proportion of patients who develop HE over the following year in a model using longitudinal data, 
stratified by risk score.  
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Figure 2: Risk of HE from Baseline Assessment by Risk Strata  
Low risk patients have baseline risk scores of <-10, Intermediate risk patients have scores between -9 and 
20, and high risk patients have scores >20.  
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tSupplementary Table 1: Medication Classes 
Benzodiazepines Gabanergic Antipsychotic Opiates Antidepressants 
Chlordiazepoxide Gabapentin aripiprazole Oxycodone citalopram 
Diazepam Pregabalin chlorpromazine Morphine bupropion 
Lorazepam  clozapine Hydromorphone venlafaxine 
Oxazepam  fluphenazine Codeine desvenlafaxine 
Alprazolam  Haloperidol Hydrocodone escitalopram 
Clonazepam  lurasidone Fentanyl fluoxetine 
Eszopiclone  Olanzapine Methadone citalopram 
Zolpidem  Quietapine  paroxetine 
Temazepam  Risperidal  vilazodone 
Triazolam  Thioridazine  sertraline 
  ziprasidone  duloxetine 
 
   Fluvoxamine 
 
   Mirtazapine 
 
   Nefazodone 
 
    
Tricyclics Statins Diuretic 
Proton pump  
inhibitor Beta blocker 
Trazodone Atorvastatin Furosemide Pantoprazole Nadolol 
Amitryptiline Rosuvastatin Spironolactone Omeprazole Propranolol 
Nortryptiline Pravastatin Amiloride Rabeprazole Carvedilol 
Desipramine Lovastatin Hydrochlorothiazide Lansoprazole  
Imipramine Simvastatin Epleronone Esomeprazole  
Doxepin  Chlorthalidone Deslansoprazole  
  Indapamide   
  Torsemide   
     
 
In supplementary table 1, the medication classes explored as exposures for HE risk are detailed 
by their constituent medications. Both generic and brand names were searched in the clinical 
data warehouse.  
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Supplementary Table 2: Incremental Changes After Including Additional Variables in 








Final model (based on Table 2) 
(albumin, bilirubin, statin, non-
selective beta-blocker) 
0.68 (0.66-0.70) 0.73 (0.71-0.75) 
Plus proton pump inhibitor use 0.68 (0.66-0.70) 0.73 (0.71-0.75) 
Plus benzodiazepine use 0.68 (0.66-0.70) 0.73 (0.71-0.75) 
Plus opiate use 0.68 (0.66-0.70) 0.73 (0.71-0.75) 
Plus antidepressant use 0.68 (0.66-0.70) 0.73 (0.71-0.75) 
Plus gabanergic use 0.68 (0.66-0.70) 0.73 (0.71-0.75) 
Plus all meds 0.68 (0.66-0.70) 0.72 (0.70-0.74) 
In Supplementary Table 2, the area under the receiver operating curve (AUC) is presented for the 
variables selected in table 2 for both baseline and longitudinal models. We demonstrate the lack 
of increased risk discrimination associated with use of selected medication classes either at 
baseline or during follow-up (longitudinal model) 
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tSupplementary Figure 1 
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